FDA adds warnings to Forest Labs' Celexa label
(Reuters) - Health regulators added new warnings to the label of Forest Laboratories Inc's antidepressant Celexa and its generic versions about a potential risk of rare heart diseases.
The changed drug label has a particular caution for patients with certain conditions because of the risk of QT syndrome -- a disorder of the heart's electrical activity.
The FDA also said the maximum recommended dose of Celexa, or citalopram, is 20 mg per day for patients older than 60 years.
(Reporting by Kavyanjali Kaushik in Bangalore; Editing by Don Sebastian)
- Target holiday cyber breach hits 40 million payment cards
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Zuckerberg to sell Facebook shares worth about $2.3 billion
- Special Report: Why Ukraine spurned the EU and embraced Russia
- Facebook, Zuckerberg, banks must face IPO lawsuit: judge
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more